---
document_datetime: 2023-09-21 20:33:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_en.pdf
document_name: xerava-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9945379
conversion_datetime: 2025-12-19 23:09:19.870308
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form                              | Route of administration   | Immediate Packaging   | Pack size                   |
|------------------|-------------------|------------|--------------------------------------------------|---------------------------|-----------------------|-----------------------------|
| EU/1/18/1312/001 | Xerava            | 50 mg      | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 vial                      |
| EU/1/18/1312/002 | Xerava            | 50 mg      | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 12 (12x1) vials (multipack) |
| EU/1/18/1312/003 | Xerava            | 100 mg     | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 vial                      |
| EU/1/18/1312/004 | Xerava            | 100 mg     | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 12 (12x1) vials (multipack) |
| EU/1/18/1312/005 | Xerava            | 100 mg     | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 vials                    |